LRRK2 G2019S-specific inhibitor
/ Acelot
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 14, 2020
ESCAPE Bio to present at the Bank of America Securities Virtual Health Care Conference
(Businesswire)
- "ESCAPE....The company recently nominated a development candidate and initiated preclinical toxicology studies for its G2019S LRRK2 inhibitor being developed as a potential treatment for Parkinson’s disease patients with a G2019S LRRK2 variant."
Preclinical • CNS Disorders • Parkinson's Disease
1 to 1
Of
1
Go to page
1